Search Results - Eunice L. Kwak

Refine Results
  1. 1
    Role for NF-κB in the Regulation of Ferritin H by Tumor Necrosis Factor-α

    Role for NF-κB in the Regulation of Ferritin H by Tumor Necrosis Factor-α by Eunice L. Kwak, Denis A. Larochelle, Carole Beaumont, Suzy V. Torti, Frank M. Torti

    Published 1995
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors by Geoffrey I. Shapiro, Eunice L. Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John F. Lyons, Daruka Mahadevan

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Familial Gastric Cancers

    Familial Gastric Cancers by Namrata Setia, Jeffrey W. Clark, Dan G. Duda, Theodore S. Hong, Eunice L. Kwak, John T. Mullen, Gregory Y. Lauwers

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Rapid Radiographic and Clinical Improvement After Treatment of a <i>MET</i>-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor

    Rapid Radiographic and Clinical Improvement After Treatment of a <i>MET</i>-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor by S. Andrew, Tracy T. Batchelor, Eunice L. Kwak, Jeffrey W. Clark, Daphne L. Wang, Keith D. Wilner, David N. Louis, A. John Iafrate

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Dose-Painted Intensity-Modulated Radiation Therapy for Anal Cancer: A Multi-Institutional Report of Acute Toxicity and Response to Therapy

    Dose-Painted Intensity-Modulated Radiation Therapy for Anal Cancer: A Multi-Institutional Report of Acute Toxicity and Response to Therapy by Lisa A. Kachnic, Henry Tsai, John J. Coen, Lawrence S. Blaszkowsky, Kevan L. Hartshorn, Eunice L. Kwak, John Willins, David P. Ryan, Theodore S. Hong

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer

    Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer by Matthew H. Kulke, Lawrence S. Blaszkowsky, David P. Ryan, Jeffrey W. Clark, Jeffrey A. Meyerhardt, Andrew X. Zhu, Peter C. Enzinger, Eunice L. Kwak, Alona Muzikansky, Colleen Lawrence, Charles S. Fuchs

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors by Geoffrey I. Shapiro, Jordi Rodón, Cynthia Bedell, Eunice L. Kwak, José Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, A. Douglas Laird, Linh T. Nguyen, Yi Xu, Coumaran Égile, Gerald M. Edelman

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    A protein and mRNA expression-based classification of gastric cancer

    A protein and mRNA expression-based classification of gastric cancer by Namrata Setia, Agoston T. Agoston, Hye Seung Han, John T. Mullen, Dan G. Duda, Jeffrey W. Clark, Vikram Deshpande, Mari Mino‐Kenudson, Amitabh Srivastava, Jochen K. Lennerz, Theodore S. Hong, Eunice L. Kwak, Gregory Y. Lauwers

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab

    Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab by Raymond Wadlow, Aram F. Hezel, Thomas A. Abrams, Lawrence S. Blaszkowsky, Charles S. Fuchs, Matthew H. Kulke, Eunice L. Kwak, Jeffrey A. Meyerhardt, David P. Ryan, Jackie Szymonifka, Brian M. Wolpin, Andrew X. Zhu, Jeffrey W. Clark

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Updated long‐term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010

    Updated long‐term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts Ge... by Sophie Cai, Theodore S. Hong, Saveli Goldberg, Carlos Fernández‐del Castillo, Sarah P. Thayer, Cristina R. Ferrone, David P. Ryan, Lawrence S. Blaszkowsky, Eunice L. Kwak, Christopher G. Willett, Keith D. Lillemoe, Andrew L. Warshaw, Jennifer Y. Wo

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer

    Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer by Sai‐Hong Ignatius Ou, Lyudmila Bazhenova, D. Ross Camidge, Benjamin Solomon, June Herman, Tatiana S. Kain, Yung‐Jue Bang, Eunice L. Kwak, Alice T. Shaw, Ravi Salgia, Robert G. Maki, Jeffrey W. Clark, Keith D. Wilner, A. John Iafrate

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

    Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors by David S. Hong, Patricia LoRusso, Omid Hamid, Filip Janků, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily Chan, Tanios Bekaii‐Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, Eunice L. Kwak

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Isolation of rare circulating tumour cells in cancer patients by microchip technology

    Isolation of rare circulating tumour cells in cancer patients by microchip technology by Sunitha Nagrath, Lecia V. Sequist, Shyamala Maheswaran, Daphne W. Bell, Daniel Irimia, Lindsey Ulkus, Matthew R. Smith, Eunice L. Kwak, Subba R. Digumarthy, Alona Muzikansky, Paula D. Ryan, Ulysses J. Balis, Ronald G. Tompkins, Daniel A. Haber, Mehmet Toner

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in<i>MET</i>-Amplified Esophagogastric Cancer

    Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in<i>MET</i>-Amplified Esophagogastric Cancer by Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong, Ryan B. Corcoran

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529

    Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529 by Devarati Mitra, Theodore S. Hong, Nora Horick, Brent S. Rose, Lorraine N. Drapek, Lawrence S. Blaszkowsky, Jill N. Allen, Eunice L. Kwak, Janet E. Murphy, Jeffrey W. Clark, David P. Ryan, James C. Cusack, Liliana Bordeianou, David L. Berger, Jennifer Y. Wo

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

    A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies by Dejan Juric, Johann S. de Bono, Patricia LoRusso, John Nemunaitis, Elisabeth I. Heath, Eunice L. Kwak, T. Macarulla Mercadé, Elena Geuna, Maria J. de Miguel, Chirag Patel, Keisuke Kuida, Serap Sankoh, Eric H. Westin, Fabian Zohren, Yaping Shou, Josep Tabernero

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    <i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

    <i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib by Jochen K. Lennerz, Eunice L. Kwak, A. B. Ackerman, Michael Michael, Stephen B. Fox, Kristin Bergethon, Gregory Y. Lauwers, James G. Christensen, Keith D. Wilner, Daniel A. Haber, Ravi Salgia, Yung‐Jue Bang, Jeffrey W. Clark, Benjamin Solomon, A. John Iafrate

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

    Phase 1/2 study of everolimus in advanced hepatocellular carcinoma by Andrew X. Zhu, Thomas A. Abrams, Rebecca A. Miksad, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Hui Zheng, Alona Muzikansky, Jeffrey W. Clark, Eunice L. Kwak, Deborah Schrag, Kathryn R. Jors, Charles S. Fuchs, A. John Iafrate, Darrell R. Borger, David P. Ryan

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

    First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer by Geoffrey I. Shapiro, Katherine M. Bell‐McGuinn, Julian R. Molina, Johanna C. Bendell, James Spicer, Eunice L. Kwak, Susan Pandya, Robert Millham, Gary Borzillo, Kristen J. Pierce, Lixin Han, Brett E. Houk, Jorge D. Gallo, María Alsina, Irene Braña, Josep Tabernero

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

    Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors by Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells A. Messersmith, Geoffrey I. Shapiro

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: